Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,468 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Completed Not applicable Interventional

A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

NCT00002325
View directory record Official record
Conditions
Mycoses, HIV Infections, Coccidioidomycosis
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

NCT01190176
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Gynaecological follow-up, Cervarix, Placebo control
Procedure · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
28 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
3
States / cities
Iowa City, Iowa • Wichita, Kansas • Wenatchee, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Prevena Spine for Use in Spine Surgery

NCT05555355
View directory record Official record
Conditions
Surgery, Incision, Surgical
Interventions
Prevena Plus 125 Therapy Unit, Spine surgery
Device · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348
View directory record Official record
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
mRNA-1653, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

NCT04029116
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • San Diego, California • Lake Worth, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

NCT00920647
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg), Idursulfase IT (30 mg)
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 31, 2026, 1:40 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

NCT04842747
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
VERU-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 1:40 PM EDT
Recruiting Phase 2 Interventional

Study With Phage for CF Subjects With Pseudomonas Lung Infection

NCT06998043
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Interventions
BX004, Placebo
Biological · Other
Lead sponsor
BiomX Ltd
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 31, 2026, 1:40 PM EDT
Not yet recruiting Not applicable Interventional

Sepsis Biomarker Monitoring in Burn Patients

NCT07866521
View directory record Official record
Conditions
Sepsis, Burn, Inflammation, Burn Infection
Interventions
PSP Monitoring
Device
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Not applicable Interventional Results available

Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department

NCT02957136
View directory record Official record
Conditions
Respiratory Tract Infections, Influenza, Human, Common Cold
Interventions
Rapid respiratory pathogen nucleic acid amplification test
Device
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 101 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Not applicable Interventional

A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients

NCT00002309
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Fort Bragg, North Carolina • Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Cardiovascular Effects of COVID-19

NCT04365699
View directory record Official record
Conditions
COVID-19
Interventions
AT-001
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

NCT00035893
View directory record Official record
Conditions
HIV Seropositivity, HIV Infection
Interventions
poly I-poly C12U
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
10
States / cities
Fountain Valley, California • Los Angeles, California • Norwalk, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 31, 2026, 1:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults

NCT05706116
View directory record Official record
Conditions
Whipworm, Trichuriasis, Controlled Human Infection
Interventions
Trichuris trichiura Egg Inoculum
Biological
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 1:40 PM EDT
Terminated Phase 1 Interventional

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

NCT01216436
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination with RNA-transfected mature autologous DC
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness of an Online Prevention Program in Reducing the Risk of STD Infection in Young Adults

NCT00255944
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Youthnet Internet-based program, Control Internet based program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 25 Years
Enrollment
2,622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 31, 2026, 1:40 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability of Z-100 in Patients With Early HIV Infection

NCT00016692
View directory record Official record
Conditions
HIV Infections
Interventions
Z-100
Drug
Lead sponsor
Zeria Pharmaceutical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2006 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

NCT00001034
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 3 Interventional

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

NCT03037164
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
4 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 1:40 PM EDT
Recruiting Phase 2 Interventional

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT07214571
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tennessee Connections for Better Birth Outcomes

NCT00502697
View directory record Official record
Conditions
Preterm Birth
Interventions
Targeted Nurse Home Visits, Conventional prenatal/postpartum care
Behavioral · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 31, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 PrEP HCW HCQ Study

NCT04354870
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine (HCQ)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 31, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

NCT06940622
View directory record Official record
Conditions
Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Interventions
D-Mannose, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 31, 2026, 1:40 PM EDT